This site uses cookies to improve your experience and to provide services and advertising. By continuing to browse, you agree to the use of cookies described in our Cookies Policy. You may change your settings at any time but this may impact on the functionality of the site. To learn more see our Cookies Policy.
Dublin: 12 °C Sunday 16 June, 2019


# elan - Tuesday 18 June, 2013

Royalty gives up bid for Irish biotech firm Elan BID

Royalty gives up bid for Irish biotech firm Elan

The US intellectual property investor Royalty Pharma said that it received ‘repeated rejections’ from Elan.

# elan - Tuesday 9 April, 2013

130 jobs to go in Alkermes' Athlone facility

The company said the decision was made following a reduction in demand for certain pharmaceutical products.

# elan - Sunday 19 August, 2012

GALLERY: The 15 most valuable companies on the Irish Stock Exchange Big Money This post contains images

GALLERY: The 15 most valuable companies on the Irish Stock Exchange

There’s been some speculation about some firms delisting from Dublin. Here are the 15 biggest ones trading here.

# elan - Monday 9 May, 2011

Elan's Athlone unit to get $1bn in merger deal

Pharmaceutical company announces multi-million deal with US drug firm Alkermes, which will then base its European headquarters in Athlone.

# elan - Tuesday 8 February, 2011

From Business ETC Elan reports first operating profits for nine years Elan

Elan reports first operating profits for nine years

The Irish pharmaceutical manufacturer reports its first first operating profit since 2001, as revenues spike.

# elan - Monday 6 September, 2010

Elan granted injunction against board members

Pharmaceutical company wants to block ‘parallel investigation’.

# elan - Friday 16 July, 2010

US INVESTIGATIONS have resulted in huge payouts by two major firms – drugmaker Elan, and the bank Goldman Sachs. The companies were fined a whopping $750 million combined after separate investigations by US officials.

Irish pharmaceutical company Elan will pay a $200 million fine to settle claims arising from a US investigation into how the company marketed its Zonegran medicine. The anti-epileptic drug was sold off by Elan in 2004, and the company had set aside $206 million to cope with costs expected to arise from the probe.

The company is also expected to plead guilty to violating the US Federal Food, Drug and Cosmetic Act, but specific details on the infraction were not released.

US bank Goldman Sachs has agreed to pay $550 million in compensation  to settle a fraud action by US regulators against the company. Regulators accused the bank of misleading investors in subprime mortgage products just as the housing market began to collapse.

They said Goldman Sachs had allowed a hedge fund to package subprime mortgages for their clients while simultaneously betting against those packages. The fine is unlikely to have much financial impact on the company, which earned $13.3 billion last year.